Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,193 matching trials from the live ClinicalTrials.gov search.
Filters: Durham, North Carolina Clear all
Completed Phase 3 Interventional Results available

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

NCT00003644
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
144
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

NCT00912093
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 31, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional Results available

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

NCT01546571
View directory record Official record
Conditions
Melanoma
Interventions
POL-103A, POL-103A without API
Biological
Lead sponsor
Polynoma LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
59
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer

NCT00049309
View directory record Official record
Conditions
Prostate Cancer
Interventions
dietary intervention, flaxseed
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Ann Arbor, Michigan • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 31, 2026, 5:27 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707
View directory record Official record
Conditions
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
Interventions
Atezolizumab, Bevacizumab, Computed Tomography, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
907
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

NCT00974311
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

NCT00708162
View directory record Official record
Conditions
HIV Infection
Interventions
Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
94
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 31, 2026, 5:27 AM EDT
Recruiting Phase 3 Interventional

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
65
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

NCT06112418
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Interventions
The Cleerly CAD Staging System
Device
Lead sponsor
Cleerly, Inc.
Industry
Eligibility
55 Years and older
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
125
States / cities
Chandler, Arizona • Scottsdale, Arizona • Sun City, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed No phase listed Observational

Prediction of Functional Outcomes From Chronic Critical Illness

NCT03159208
View directory record Official record
Conditions
Chronic Critical Illness, Prolonged Mechanical Ventilation
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Denver, Colorado • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

NCT00000750
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 9 Months
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 31, 2026, 5:27 AM EDT
Recruiting Phase 3 Interventional

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318
View directory record Official record
Conditions
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Interventions
Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
288
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 31, 2026, 5:27 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025
View directory record Official record
Conditions
Solid Cancer
Interventions
R-DXd, Paclitaxel, Topotecan, PLD
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
45
States / cities
Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NCT03274687
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
229
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed No phase listed Observational

Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

NCT00050284
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

NCT00003955
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 31, 2026, 5:27 AM EDT
Recruiting Phase 2Phase 3 Interventional

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Interventions
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
6 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

NCT00003593
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
109
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 31, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

NCT00738387
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ASA404, Placebo, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
88
States / cities
Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Not applicable Interventional Results available

TSolution One® Total Knee Arthroplasty

NCT03017261
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
TSolution One®
Device
Lead sponsor
Think Surgical Inc.
Industry
Eligibility
21 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Hackensack, New Jersey • New York, New York • Roslyn, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 31, 2026, 5:27 AM EDT
Not listed Phase 1Phase 2 Interventional

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

NCT03168061
View directory record Official record
Conditions
Solid Tumor, Soft Tissue Sarcoma, Metastatic Sarcoma, Sarcoma
Interventions
NC 6300
Drug
Lead sponsor
NanoCarrier Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Duarte, California • Santa Monica, California • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 31, 2026, 5:27 AM EDT
Completed Not applicable Interventional Results available

Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System

NCT04341948
View directory record Official record
Conditions
Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
Interventions
SPRINT Peripheral Nerve Stimulation (PNS) System
Device
Lead sponsor
SPR Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 31, 2026, 5:27 AM EDT